Premium
Results of induction and consolidation treatment with intermediate and high‐dose cytosine arabinoside and m‐Amsa of patients with poor‐risk acute myelogeneous leukaemia
Author(s) -
Peters W. G.,
Willemze R.,
Colly L. P.
Publication year - 1988
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1988.tb00824.x
Subject(s) - medicine , cytarabine , chemotherapy , cytosine , leukemia , gastroenterology , bone marrow , refractory (planetary science) , induction chemotherapy , surgery , dna , physics , biology , astrobiology , genetics
50 patients (aged 18–58 years) with acute myelogenous leukaemia after a preleukaemic phase (n = 14), acute myelogenous leukaemia that previously failed to respond to conventional chemotherapy (n = 9) or relapsed disease (n = 27) were given remission induction therapy consisting of cytosine arabinoside (1 g/m 2 q 12 h × 12) and m‐Amsa (115 mg/m 2 for 1 or 3 days). Overall, 27 patients (54%) achieved complete remission. The complete remission rate for patients with acute myelogenous leukaemia after a preleukaemic phase (7/14) and those with primary refractory or relapsed leukaemia (20/36) seems superior to that obtained with conventional remission‐induction therapy. 12 patients received 1–3 courses of consolidation chemotherapy with cytosine arabinoside (3 g/m 2 q 12 h × 8) and m‐Amsa (115 mg/m 2 for 1 d). 3 of them subsequently underwent autologous bone marrow transplantation. The median duration of remission for the remaining 9 patients was 8 months. 11 patients did not receive consolidation therapy; their median duration of remission was 3 months. The difference between the two groups was not significant. 4 patients underwent allogeneic bone marrow transplantation after achievement of complete remission. The impact of high‐dose cytosine arabinoside consolidation chemotherapy on poor‐risk acute myelogenous leukaemia remains unclear.